DePuy recalls knee replacement implants with part code 152307001 due to potential surgery delays from improper screws. Affected units sold between 2020-2022.
“DePuy ATTUNE Revision Tibial Augment Size 7/8 5mm Recall: Surgery Delay Risk.” GovInfoNow, updated August 19, 2026. https://govinfonow.com/recall/61816-depuy-attune-revision-tibial-augment-size-7-8-5mm-recall. Based on FDA recall #Z-0074-2022 (https://api.fda.gov/device/enforcement.json?search=recall_number:%22Z-0074-2022%22&limit=1).
The FDA announced on Sept. 9, 2021, that DePuy Orthopaedics, Inc. is recalling ATTUNE Revision Tibial Augment Size 7/8 5mm knee joint replacement parts due to packaging errors. The hazard involves unintended screws that may cause surgical delays. Owners should contact the company for a remedy.
How to tell if you have it
Brand: DePuy
Product: ATTUNE Revision Tibial Augment Size 7/8 5mm- intended for knee joint replacement Part Code:152307001
UPC: 10603295057642
Lot Number: J6304Z
The hazard
The packaging may include screws that are not intended to be used with the 5mm augments, which may cause delay in surgery.
Context
GovInfoNow's records show DePuy Orthopaedics, Inc. has 23 other recalls on record since July 12, 2017. Other recent recalls of similar products include DePuy Orthopaedics Recalls ATTUNE Knee Component Due to Incorrect Labeling (March 12, 2024), DePuy Attune Revision Limb Preservation System Tibial Insert Recall: Radiation Dose Risk (Feb. 15, 2023), and DePuy ATTUNE Sizing Guide Recall: Corroded Spring Risks Surgical Complications (June 29, 2022).
How to tell if you have this one
Check for part code 152307001 on the implant packaging. The recall covers units sold between 2020 and 2022 with lot number J6304Z.
Brand
DePuy
Product
ATTUNE Revision Tibial Augment Size 7/8 5mm
Category
Medical device
Based on the official FDA remedy
What to do — step by step
Check Implant Packaging
Look for part code 152307001 on the packaging to confirm if your implant is affected.
Where it went and when
Where it was distributed
Distributed nationwide; the notice names 10 states.
Named in the notice
Covered by “nationwide”
Not listed
FDA distribution: “US Nationwide distribution in the states of CA, LA, MN, MO, NC, NE, OR, PA, WA, WI.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Named in the notice: California, Louisiana, Minnesota, Missouri, Nebraska, North Carolina, Oregon, Pennsylvania, Washington, Wisconsin.
Recall timeline
FDA terminated this recall 23 months after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #Z-0074-2022 (September 9, 2021) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for Z-0074-2022 to see it in context.
Plain-language summary written by qwen3:4b on August 19, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.